Nanomedicine promotes ferroptosis to inhibit tumour proliferation in vivo.
Nanomedicine promotes ferroptosis to inhibit tumour proliferation in vivo.
复制标题
纳米医学促进铁死亡抑制体内肿瘤增殖
DOI：
10.1016/j.redox.2021.101908
复制
发表时间：
2021-06
期刊：
影响因子：
11.4
通讯作者：
Guo Y
中科院分区：
文献类型：
--
作者：
Luo Y;Niu G;Yi H;Li Q;Wu Z;Wang J;Yang J;Li B;Peng Y;Liang Y;Wang W;Peng Z;Shuai X;Guo Y
miR-101- 3 p可能在多种肿瘤中发挥治疗作用。然而，其抗肿瘤机制仍不清楚，并且缺乏体内治疗肿瘤细胞的明确策略。本研究的目的是探讨miR-101- 3 p对肿瘤细胞的抑制机制，并开发相关的纳米药物用于体内治疗。检测miR-101- 3 p及其靶蛋白TBLR 1在肿瘤组织和细胞中的表达水平，并阐明其与铁凋亡的关系。此外，评价了纳米载体在实现体内治疗性基因递送中的功效。纳米医学得到了进一步发展，使用皮下异种移植癌症模型验证了抗增殖的体内治疗效果。miR-101- 3 p的表达水平与临床肿瘤大小和TNM分期呈负相关。miR-101- 3 p通过直接靶向TBLR 1恢复肿瘤细胞中的铁凋亡，这反过来促进凋亡并抑制增殖。我们开发了可以将miR-101- 3 p递送到体内肿瘤细胞以实现铁凋亡恢复以及抑制体内肿瘤增殖的纳米药物。miR-101- 3 p/TBLR 1轴在肿瘤铁凋亡中起重要作用。增加miR-101- 3 p水平的纳米药物可能是抑制肿瘤增殖的有效疗法。
miR-101–3p may play a therapeutic role in various tumours. However, its anti-tumour mechanism remains unclear, and a definitive strategy to treat tumour cells in vivo is lacking. The objective of this study was to investigate the inhibitory mechanism of miR-101–3p on tumour cells and to develop relevant nanomedicines for in vivo therapy. The expression levels of miR-101–3p and its target protein TBLR1 in tumour tissues and cells were detected, and their relationship with ferroptosis was clarified. Furthermore, the efficacy of nanocarriers in achieving in vivo therapeutic gene delivery was evaluated. Nanomedicine was further developed, with the anti-proliferative in vivo therapeutic effect validated using a subcutaneous xenograft cancer model. The expression level of miR-101–3p negatively correlated with clinical tumour size and TNM stage. miR-101–3p restores ferroptosis in tumour cells by directly targeting TBLR1, which in turn promotes apoptosis and inhibits proliferation. We developed nanomedicine that can deliver miR-101–3p to tumour cells in vivo to achieve ferroptosis recovery, as well as to inhibit in vivo tumour proliferation. The miR-101–3p/TBLR1 axis plays an important role in tumour ferroptosis. Nanopharmaceuticals that increase miR-101–3p levels may be effective therapies to inhibit tumour proliferation.
登录
查看更多内容
影响因子：
2.9
作者：
Li, Ke;Jiang, Yongxin;Zhuang, Li
通讯作者：
Zhuang, Li
SOX7在肝癌发生中的抑制作用
影响因子：
3.7
作者：
Wang C;Guo Y;Wang J;Min Z
通讯作者：
Min Z
DOI：
10.1007/978-1-0716-0247-8_11
发表时间：
2020-01-01
期刊：
IMMUNE MEDIATORS IN CANCER: METHODS AND PROTOCOLS
影响因子：
--
作者：
Martinez, Alejandra M.;Kim, Ahryun;Yang, Wan Seok
通讯作者：
Yang, Wan Seok
铁死亡调节剂谷胱甘肽过氧化物酶 4 的新型变构激活剂
影响因子：
7.3
作者：
Li, Cong;Deng, Xiaobing;Lai, Luhua
通讯作者：
Lai, Luhua
影响因子：
3.1
作者：
Mei, Yong;Jiang, Pinping;Zhang, Jinsong
通讯作者：
Zhang, Jinsong